Related Experiment Video

Updated: May 19, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer

James W Antoon1, Martin D White, Jennifer L Driver

  • 1Tulane Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA 70112, USA.

Experimental Biology and Medicine (Maywood, N.J.)
|August 4, 2012
PubMed

Insights

Two sphingosine kinase inhibitors show promise for breast cancer treatment. They are more effective in triple-negative breast cancer cells than luminal cells, indicating potential therapeutic applications.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Sphingosine kinase (Sphk) signaling is a growing area of interest for cancer therapy.
  • Sphingosine kinase inhibitors (SKI)-II and ABC294640 are potential breast cancer treatments.
  • Limited data exists on their efficacy across diverse breast cancer subtypes.

Purpose of the Study:

  • To characterize the efficacy of SKI-II and ABC294640 in luminal, endocrine-resistant, and basal-A triple-negative breast cancer cells.
  • To compare their effectiveness with existing data in other breast cancer models.
  • To investigate the role of Sphk expression in breast cancer survival and endocrine therapy resistance.

Main Methods:

  • Drug efficacy testing of SKI-II and ABC294640 in MDA-MB-361 (luminal, endocrine-resistant) and MDA-MB-468 (basal-A, triple-negative) breast cancer cells.
  • Comparison with previously published data.
  • In vitro and in vivo studies of ABC294640 in triple-negative breast cancer models.
  • Analysis of Sphk expression's impact on cell survival and therapy resistance.

Main Results:

  • Both SKI-II and ABC294640 exhibited greater efficacy in basal-A (triple-negative) breast cancer cells compared to luminal cells.
  • ABC294640 demonstrated significant apoptosis induction and proliferation inhibition in vitro and in vivo in triple-negative models.
  • Elevated Sphk expression was found to promote cancer cell survival and resistance to endocrine therapy.

Conclusions:

  • Sphingosine kinase inhibitors show differential efficacy across breast cancer subtypes, with greater potential in triple-negative breast cancer.
  • ABC294640 is a particularly promising agent for triple-negative breast cancer treatment.
  • Targeting Sphk signaling may offer a strategy to overcome endocrine therapy resistance.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: